<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00439192</url>
  </required_header>
  <id_info>
    <org_study_id>ELB245201-06</org_study_id>
    <nct_id>NCT00439192</nct_id>
  </id_info>
  <brief_title>ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Group, Phase II, Forced Dose Titration Study to Investigate the Efficacy and Safety of 400mg and 600mg ELB245 Given Once Daily for 12 Weeks (8 + 4 Weeks) Versus Placebo and Versus 4mg Tolterodine Given Once Daily in Patients With Incontinent Overactive Bladder (OAB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>elbion AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>elbion AG</source>
  <brief_summary>
    <textblock>
      This study is designed to determine the efficacy of escalating doses of ELB245 versus placebo
      , when administered to patients with OAB and to compare the efficacy of escalating doses of
      ELB245 versus the standard treatment tolterodine, when administered to patients with OAB.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    side effect profile did not match expectations
  </why_stopped>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean number of micturitions</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>OAB related measures</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urgency measures</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Urinary Incontinence</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ELB245</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients at least 18 years of age

          -  Symptoms of OAB for a minimum of 3 consecutive months prior to study entry; severity
             of OAB (as defined by patient reported symptoms) for a minimum of one month prior to
             study entry

          -  Ability to use a toilet independently and without difficulty

          -  No treatment with any medication against OAB during the 4 weeks prior to study entry

          -  Written informed consent

        Exclusion Criteria:

          -  Breastfeeding women, pregnant women or women who intend to become pregnant during the
             study or women of childbearing potential who are sexually active and not practicing a
             highly reliable method of birth control

          -  Any local pathology, that might cause the bladder symptoms

          -  Significant stress urinary incontinence or mixed stress/urgency incontinence

          -  Any neurological disease affecting bladder function or muscle strength

          -  Patient history of any lower urinary tract surgery or previous pelvic irradiation

          -  Local administration of botulinum toxin within the last 9 months in the lower urinary
             tract

          -  Start or change of a behavioral bladder training program

          -  Post voiding residual volumes larger than 250ml or symptoms of clinically relevant
             bladder outlet obstruction

          -  Nocturial polyuria

          -  History of liver disease and/or impaired liver function

          -  Cholestasis

          -  Chronic alcohol or drug abuse

          -  Evidence of significantly impaired renal function (

          -  Diabetes mellitus (type I or II) with significant peripheral neuropathy and/or
             polyuria

          -  Inflammatory bowel disease such as Crohn's disease, or ulcerative colitis

          -  Uncontrolled narrow angle glaucoma

          -  Chronic use of carbamazepine or paracetamol

          -  Participation in any drug study in the preceding 3 months

          -  Concomitant treatment with strong CYP3A4 inhibitors

          -  History or evidence of relevant cardiovascular or cerebrovascular disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Michel, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. Pharmacology &amp; Pharmacotherapy, AMC, University of Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Private Gynecological Practice</name>
      <address>
        <city>Alzey</city>
        <zip>55232</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Berlin</city>
        <zip>12247</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Berlin</city>
        <zip>13057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Borken</city>
        <zip>46325</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Duisburg</city>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Duisburg</city>
        <zip>47179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Greifswald</city>
        <zip>17493</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Hamburg</city>
        <zip>20097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Homburg Saar</city>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Kleinblittersdorf</city>
        <zip>66271</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Muelheim</city>
        <zip>45468</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Munich</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>MÃ¼hlacker</city>
        <zip>75417</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Oberursel</city>
        <zip>61440</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Urologic Practice</name>
      <address>
        <city>Stuttgart</city>
        <zip>70372</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Medyczne dr n. med. Artur Racewicz</name>
      <address>
        <city>Bialystok</city>
        <zip>15-337</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urovita Sp z o.o.</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Invicta Sp z o.o.</name>
      <address>
        <city>Gdansk</city>
        <zip>80-850</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny w Koscierzynie, Dep. Oddzial Urologii</name>
      <address>
        <city>Koscierzyna</city>
        <zip>83-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Specjalista Sp. z o.o.</name>
      <address>
        <city>Kutno</city>
        <zip>99-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Nasz Lekarz, Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny - Centrum Leczenia Obrazen &quot;Dzieciatka Jezus&quot;</name>
      <address>
        <city>Warszawa</city>
        <zip>02-005</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Leczenia Chorob Cywilizacyjnych Andrzej Opadczuk</name>
      <address>
        <city>Warszawa</city>
        <zip>02-777</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EMC Instytut Medyczny S.A., EuroMediCare, Szpital Specjalistyczny z Przychodnia</name>
      <address>
        <city>Wroclaw</city>
        <zip>54-144</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital LinkÃ¶ping</name>
      <address>
        <city>LinkÃ¶ping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danderyds Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Uppsala</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2007</study_first_submitted>
  <study_first_submitted_qc>February 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2007</study_first_posted>
  <last_update_submitted>August 7, 2007</last_update_submitted>
  <last_update_submitted_qc>August 7, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2007</last_update_posted>
  <keyword>OAB, proof of concept</keyword>
  <keyword>Overactive Bladder (OAB)</keyword>
  <keyword>with incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolterodine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

